<DOC>
	<DOC>NCT00507845</DOC>
	<brief_summary>Primary: - To assess effectiveness of Ramipril-Felodipine in hypertensive Argentinean patients Secondary: - To assess tolerability of Ramipril-Felodipine in hypertensive Argentinean patients.</brief_summary>
	<brief_title>Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Felodipine</mesh_term>
	<criteria>Outpatient Patients who couldn´t control their hypertension after 6 weeks of treatment with monotherapy (calcium blockers, beta blockers, diuretics, ACE inhibitors, AT2 blockers)(uncontrolled hypertension). Already on fixeddose combination treatment for hypertension Contraindication to angiotensin converting enzyme (ACE) inhibitors or CCB therapy Known hypersensitivity to felodipine (or other dihydropyridines), ramipril, other ACE or any of the excipients of ramipril felodipine. History of angioedema Unstable haemodynamic conditions: cardiovascular shock, untreated heart failure, acute myocardial infarction, unstable angina pectoris, stroke. Patients with AV block II or III Severely impaired hepatic function. Preexisting bilateral renal artery stenosis or stenosis of the artery to a solitary kidney Pregnant and lactating mothers Patients on dialysis or haemofiltration. Patients with creatinine clearance &lt; 20ml/min Use of potassium sparing diuretics Severe hypertension (SBP ≥ 180 mmhg or DBP ≥ 110 mmhg) The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>